Vitamin K antagonists (VKAs) are the standard of care for patients with rheumatic heart disease related atrial fibrillation. Rivaroxaban is an anticoagulant used to treat and prevent blood clots. In this touchCARDIO interview, we speak with Professor Ganesan Karthikeyan (All India Institute of Medical Sciences, New Delhi, India) to discuss the risk factors of stroke in patients with rheumatic heart disease and the potential benefits of rivaroxaban over VKAs.
The abstract entitled ‘INVICTUS – Rivaroxaban versus VKA for rheumatic atrial fibrillation’ was presented at the European Society of Cardiology (ESC) Congress 2022, 26 – 29 August 2022.
- What factors influence stroke risk in patients with rheumatic heart disease? (0:25)
- What are the potential advantages of rivaroxaban over vitamin K antagonists (VKAs) for prevention of stroke or systemic embolism in patients with rheumatic valvular heart disease? (2:04)
Disclosures: Ganesan Karthikeyan has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.
Filmed as a highlight of ESC 2022
Share this Video
Related Videos In Cardiovascular Disease
Divaka Perera, ESC 2022: Percutaneous revascularisation in patients with severe ischaemic cardiomyopathy, the REVIVED trial
The REVIVED study aimed to assess whether the addition of stents when treating patients with severe ischaemic cardiomyopathy would be beneficial to patient outcomes. In this touchCARDIO interview, we speak with Professor Divaka Perera (King’s College London, London, UK) to discuss the REVIVED trial, its outcomes and how they will affect the current treatment paradigm. […]
Divaka Perera, ESC 2022: The unmet needs in patients with heart failure due to ischaemic cardiomyopathy
In an ideal scenario, patients with ischaemic cardiomyopathy would receive specific treatment options beyond the general heart failure management currently in place. In this touchCARDIO interview, we speak with Professor Divaka Perera (King’s College London, London, UK) to discuss the unmet needs in this population and give an evaluation of surgical and percutaneous revascularization in […]
Isla Mackenzie, ESC 2022: Allopurinol for ischaemic heart disease, the ALL-HEART study
The ALL-HEART study is the first large, randomised trial assessing allopurinol in patients with ischaemic heart disease. In this touchCARDIO interview, we speak with Professor Isla Mackenzie (University of Dundee, Dundee, Scotland) to discuss the rationale for the ALL-HEART study, its findings and the future of allopurinol in ischaemic heart disease. The abstract entitled ‘ALL-HEART […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!